Additionally, we found the majority (67%) of the glioma patients, and in particular almost all HGG patients (94%), to be uPAR-PET positive, which may be encouraging for further development of uPAR-PRRT for use in HGG patients. This evidence concerns the gene PLAUR and central nervous system cancer.